New drug combo targets Hard-to-Treat lung cancer mutation

NCT ID NCT07252739

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This study tests a new targeted therapy pill called MK-1084, alone or with other drugs, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if the treatment is safe and can shrink tumors. About 130 participants will be enrolled in this Phase 2 trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-1084 (a targeted therapy pill for KRAS G12C mutations) combined with pembrolizumab (Keytruda), cetuximab, carboplatin, or pemetrexed
What this could lead to: If successful, this could provide a new first-line treatment option for people with a specific genetic subtype of lung cancer, potentially shrinking tumors and delaying progression.
What could go wrong: This is an early Phase 2 study with a small number of participants, so results may not apply broadly. The drug combination may cause side effects or fail to improve outcomes compared to existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
RECRUITING

Bangkok, Bangkok, 10300, Thailand
Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
RECRUITING

Adana, 1250, Turkey (Türkiye)
COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
RECRUITING

Cherkasy, Cherkasy Oblast, 18009, Ukraine
Centro de Oncología de Precisión ( Site 0160)
RECRUITING

Santiago, Region M. de Santiago, 7560908, Chile
Clermont Oncology Center ( Site 0041)
RECRUITING

Clermont, Florida, 34711, United States
Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
RECRUITING

Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine
Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
RECRUITING

Vinnitsya, Vinnytsia Oblast, 21029, Ukraine
Deventer Ziekenhuis ( Site 0272)
RECRUITING

Deventer, Overijssel, 7416 SE, Netherlands
Erciyes University ( Site 0145)
RECRUITING

Talas, Kayseri, 38039, Turkey (Türkiye)
Evangelismos General Hospital of Athens ( Site 0200)
RECRUITING

Athens, Attica, 106 76, Greece
Faculty of Medicine Siriraj Hospital ( Site 0350)
RECRUITING

Bangkok, Bangkok, 10700, Thailand
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
RECRUITING

Milan, Lombardy, 20133, Italy
Fundacion Arturo Lopez Perez ( Site 0167)
RECRUITING

Santiago, Region M. de Santiago, 7500921, Chile
HYKS Syöpätautien klinikka ( Site 0260)
RECRUITING

Helsinki, Uusimaa, 00290, Finland
Hacettepe Universite Hastaneleri ( Site 0140)
RECRUITING

Ankara, 6230, Turkey (Türkiye)
Hong Kong Integrated Oncology Centre ( Site 0232)
RECRUITING

Central, 0000, Hong Kong
Hong Kong United Oncology Centre ( Site 0231)
RECRUITING

Kowloon, Hong Kong
Hospital Universitario Virgen de la Macarena ( Site 0093)
RECRUITING

Seville, 41009, Spain
Koç Üniversitesi Hastanesi ( Site 0142)
RECRUITING

Adana, 34010, Turkey (Türkiye)
Kuopion Yliopistollinen Sairaala ( Site 0261)
RECRUITING

Kuopio, Northern Savonia, 70200, Finland
LIMITED LIABILITY COMPANY "MEDICAL CENTER "DOBROBUT-CLINIC" ( Site 0138)
RECRUITING

Kyiv, 03151, Ukraine
Leids Universitair Medisch Centrum ( Site 0273)
RECRUITING

Leiden, South Holland, 2333 ZA, Netherlands
Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
RECRUITING

Kropyvnytskyi, Kirovohrad Oblast, 25011, Ukraine
Liv Hospital Ankara ( Site 0146)
RECRUITING

Ankara, 06680, Turkey (Türkiye)
Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
RECRUITING

Lviv, Lviv Oblast, 79059, Ukraine
Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
RECRUITING

Kryvyi Rih, Dnipropetrovsk Oblast, 50000, Ukraine
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
RECRUITING

Nanjing, Jiangsu, 210000, China
Queen Mary Hospital ( Site 0230)
RECRUITING

Pokfulam, Hong Kong
Sanford Cancer Center Oncology Clinic ( Site 0038)
RECRUITING

Sioux Falls, South Dakota, 57104, United States
Sanford Health Roger Maris Cancer Center ( Site 0039)
RECRUITING

Fargo, North Dakota, 58102, United States
Severance Hospital Yonsei University Health System ( Site 0080)
RECRUITING

Seoul, 03722, South Korea
The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
RECRUITING

Nanchang, Jiangxi, 330209, China
Turku University Hospital ( Site 0262)
RECRUITING

Turku, Southwest Finland, 20520, Finland
Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
RECRUITING

Uzhhorod, Zakarpattia Oblast, 88000, Ukraine
VISION PARTNER Medical Centre ( Site 0135)
RECRUITING

Kyiv, 03022, Ukraine
Vaasan Keskussairaala ( Site 0263)
RECRUITING

Vaasa, Pohjanmaa, 65130, Finland
West China Hospital, Sichuan University ( Site 0315)
RECRUITING

Chengdu, Sichuan, 610066, China
Zhongshan Hospital Fudan University ( Site 0319)
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.